MBS should be prioritized in patients with larger weight loss required and those with severe obesity-related comorbidities, such as T2D or intolerance to GLP-1 RA (GIP RA). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.